Cancer remains the first or second main cause of death in developed countries. In the world, 7.6 million people died of cancer in 2005 [1]. However, the cure for advanced cancer in major cancers has not improved in the past 50 years, although chemotherapy is supposed to be a last resort, if not all [2,3]. One of the recent successful stories in cancer chemotherapy is imatinib (Gleevec®), a drug for chronic myeloid leukemia (CML) which is an inhibitor of BCR/ABL tyrosine kinase, a product of oncogene. Imatinib shows a remarkable therapeutic effect against CML while a natural course of life span of CML patients is about 5 years. However, upon blastic period when the leukemic cell growth becomes exponential, majority of patients developed drug resistance within 6 months. Therefore, one can conclude that imatinib contributes only 10% prolongation of the life span. © 2009 Springer-Verlag New York.
CITATION STYLE
Seki, T., Fang, J., & Maeda, H. (2009). Tumor-targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. In Pharmaceutical Perspectives of Cancer Therapeutics (pp. 93–120). Springer US. https://doi.org/10.1007/978-1-4419-0131-6_3
Mendeley helps you to discover research relevant for your work.